Morgan Stanley lowered the firm’s price target on Pfizer (PFE) to $32 from $33 and keeps an Equal Weight rating on the shares. Ahead of Q3 earnings, the firm adjusted models for IQVIA trends as well as intra-quarter updates, the analyst tells investors in a preview for the biopharma group.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- GoodRx Stock (GDRX) Pops as U.S. Pharmacies Unite to Lobby for TrumpRx Participation
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports
- Trump Trade: Generics to be excluded from pharma tariff plan
- Generics to be excluded from Trump’s pharma tariff plan, WSJ reports
- Arvinas price target raised to $16 from $14 at Piper Sandler